













PIPELINE OF INVESTIGATIONAL THERAPIES#:					
PROGRAM (TARGET)	THERAPEUTIC AREA	INDICATION	PHASE 1	PHASE 2	PHASE 3
valbenazine* (VMAT2 Inhibitor)	Neuropsychiatry	Adjunctive Treatment of Schizophrenia			
valbenazine* (VMAT2 Inhibitor)	Neurology	Dyskinetic Cerebral Palsy			
osavampator/NBI-'845 [±] (AMPA)	Neuropsychiatry	Inadequate Response to Treatment in Major Depressive Disorder			
NBI-'568 (M4 Agonist)	Neuropsychiatry	Schizophrenia			
NBI-'770 [§] (NMDA NR2B NAM)	Neuropsychiatry	Major Depressive Disorder			
NBI-'570 (M1/M4 Agonist)	Neuropsychiatry	Schizophrenia			
NBI-'567 ^{, ¶} (M1 Agonist)	Neuropsychiatry	CNS Indications			
NBI-'569 (M4 Agonist)	Neuropsychiatry	CNS Indications			
NBI-'986 (M4 Antagonist)	Neurology	Movement Disorders			
NBI-'890 (VMAT2 Inhibitor)	Neuropsychiatry	CNS Indications			
NBI-'355 (Na _v 1.2/1.6)	Neurology	Epilepsy			
NBI-'675 (VMAT2 Inhibitor)	Neuropsychiatry	CNS Indications			

Neurocrine Biosciences has global rights, unless otherwise noted.

*Mitsubishi Tanabe Pharma Corporation has commercialization rights in Japan and other select Asian markets.

±Takeda Pharmaceutical Company Limited has retained rights in Japan.

§Licensed from Takeda Pharmaceutical Company Limited.

^{||} Licensed from Nxera Pharma.

[¶]Nxera Pharma has retained rights in Japan; Neurocrine Biosciences may opt-in to a 50:50 cost and revenue share upon certain development events.

Investigational therapies are not approved for use in any country

